Individualized strategy for clopidogrel suspension in patients undergoing off-pump coronary surgery for acute...

Area of Science:

• Cardiology
• Cardiovascular Surgery
• Hematology

Background:

• Patients undergoing urgent coronary artery bypass graft (CABG) surgery often have prior clopidogrel exposure, increasing bleeding risks.
• Clopidogrel response and platelet function recovery vary significantly, complicating surgical timing decisions.

Purpose of the Study:

• To evaluate the utility of point-of-care platelet function testing in guiding the optimal timing for off-pump coronary artery bypass graft (CABG) surgery.
• To compare surgical outcomes in patients managed with a platelet function test-guided strategy versus standard protocols.

Main Methods:

• A case-control study involving 300 patients undergoing off-pump CABG for acute coronary syndrome.
• Group A (n=100) underwent surgery guided by point-of-care platelet function testing after clopidogrel exposure.
• Compared with propensity score-matched groups: Group B (n=100) had surgery after the standard 5-day clopidogrel cessation, and Group C (n=100) had no clopidogrel exposure.

Main Results:

• Group A demonstrated significantly reduced postoperative bleeding (523±202 mL vs 851±605 mL) and lower packed red blood cell (PRBC) transfusion requirements (1.2±1.6 vs 1.9±1.8 units) compared to Group B.
• Postoperative bleeding and PRBC transfusion in Group A were similar to Group C (no clopidogrel exposure).
• No significant differences were observed in mortality, reoperation rates, or blood-derived product consumption across groups. Group A patients waited an average of 3.6±1.7 days, with an overall reduction of 280 hospital days.

Conclusions:

• A strategy utilizing point-of-care platelet function testing optimizes CABG timing in clopidogrel-treated patients.
• This approach significantly decreases postoperative bleeding and blood product usage.
• The guided strategy leads to shorter waiting times for surgery compared to current clinical practices.